China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
PHILADELPHIA, March 02, 2017 -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that Jeffrey D. Marrazzo, chief executive officer, will present at the Cowen and Company 37th Annual Health Care Conference, on Monday, March 6, at 3:20 p.m. EST, at the Boston Marriott Copley Place in Boston.
An audio recording of Marrazzo’s presentation will be available on the "Events" section of sparktx.com/investors-media for 90 days following the conference. To access his presentation slide deck, please visit "Investor Presentations" on the Investors page.
Company management also will present at the Barclays Global Healthcare Conference, on Wednesday, March 15, at 4:20 p.m. EST, at the Loews Miami Beach Hotel in Miami.
About Spark Therapeutics
Spark Therapeutics, a fully integrated company, strives to challenge the inevitability of genetic disease by discovering, developing, and delivering gene therapies that address inherited retinal diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by targeting the liver. Our validated platform successfully has delivered proof-of-concept data with investigational gene therapies in the retina and liver. Our most advanced investigational candidate, voretigene neparvovec, in development for the treatment of biallelic RPE65-mediated IRD, has received orphan designations in the U.S. and European Union, and breakthrough therapy designation in the U.S. The pipeline also includes SPK-7001 in a Phase 1/2 trial for choroideremia, and two hemophilia development programs: SPK-9001 (which also has received both breakthrough therapy and orphan product designations) in a Phase 1/2 trial for hemophilia B being developed in collaboration with Pfizer, and SPK-8011, in a Phase 1/2 trial for hemophilia A to which Spark Therapeutics retains global commercialization rights. To learn more about us and our growing pipeline, visit www.sparktx.com.
Investor Relations Contact: Ryan Asay [email protected] (215) 239-6424 Media Contact: Monique da Silva [email protected] (215) 282-7470
